Viage Therapeutics

Large logo of Viage Therapeutics


Flag of United States of AmericaUnited States of America

Viage Therapeutics is a neuroscience-centered firm established on a foundation of innovative neurotherapeutics. DGX-001, Viage's primary clinical-stage prospect, represents a pioneering oral drug candidate aiming at the gut-brain axis. The proposed mode of action of DGX-001 is to regulate the vagus nerve through specific receptor interactions on enteroendocrine cells in the gut, leading to the regulation of brain cell activity. Viage's portfolio consists of both original neuropeptides and 2nd generation DGX-001-derived peptides and small molecules. The organization is headquartered in the San Francisco Bay Area. Vigeo was co-founded by Randolph Watnick, Ph.D., a leader in comprehending the role of the tumor microenvironment in metastasis, and Jing Watnick, Ph.D., M.B.A., an accomplished research scientist and leader in biopharmaceutical development. To fund the advancement of its science and its organization, Vigeo has collaborated with Morningside Venture Investments, Ltd, a private equity and venture capital firm established in 1992. Vigeo has secured Series A and B rounds of financing in 2015 and 2018, respectively. Vita is a cell engineering firm utilizing induced pluripotent stem cell technology to engineer particular cell types designed to substitute those that are faulty in patients. Vita is advancing its primary program, VTA-100 for the treatment of limb-girdle muscular dystrophy (LGMD2A). Vita is developing this exclusive cellular therapies following a dual development strategy beginning with autologous-derived cells before progressing to a universal hypoimmunogenic cell line. At Vivace Therapeutics, we pursue our work with enthusiasm, driven by a belief to support individuals in combating cancer and living life to the maximum. Based in the San Francisco Bay Area, Vivace Therapeutics is an oncology-focused small molecule drug discovery and development company adopting a cost-effective approach to bring innovative therapies to patients in need. Our seasoned management team and first-rate scientists labor to progress encouraging drugs and therapeutic technologies that we trust can aid in overcoming cancer.